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ABSTRACT 
Objective: To develop a ratio-derivative spectrophotometric method for the simultaneous quantification of acetilsalycilic acid (ASA), 
acetaminophen (ACE), and caffeine (CAF) in fixed-dose combination formulations. The proposed method was applied to the reference drug product 
Excedrin® in dissolution studies. 
Methods: The method is based on the use of the first-and second-derivatives of the ratio spectra and measurements at zero-crossing wavelengths. 
The dissolution profiles of ASA, ACE, and CAF were obtained following pharmacopeial conditions, USP Apparatus 2 at 100 rpm and 900 ml of water. 
Dissolution samples were treated with the proposed UV-derivative method and the results were compared with those obtained with a validated 
HPLC procedure. The dissolution efficiency was used to compare dissolution profiles (HPLC vs. UV-derivative method). 
Results: The method was linear in the range of 5-25 µg/ml of ASA, 2.5-20 µg/ml of ACE, and 1-8 µg/ml of CAF (R2>0.999, *P<0.05). The precision 
and accuracy of synthetic mixtures were within acceptable criteria (2.11-3.43% and 96.78-104.15%, respectively). Nitrocellulose filters were the 
best option to filter samples and stability of all drugs was adequate when standard solutions were stored at 4 °C during 24 h. No significant 
differences were found between dissolution profiles (*P>0.05). 
Conclusion: The proposed UV-derivative method allows the simultaneous determination of ASA, ACE, and CAF in commercial formulations. The 
method is simple, accurate, and precise and can be used in dissolution studies. Spectrophotometric methods are of low cost and harmless to the 
environment and, therefore, a better alternative than chromatographic methods. 
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Acetylsalicylic acid (ASA), acetaminophen (ACE), and caffeine (CAF) 
are often available in fixed-dose combination formulations. ASA 
possesses antirheumatic, antipyretic, and analgesic properties and is 
probably the major consumed drug in the world. ACE, also known as 
paracetamol, is an antipyretic and analgesic drug, which in contrast 
with ASA, it has the advantage of not irritating the gastrointestinal 
mucosa. The effect of both drugs on pain relief can be enhanced by 
CAF [1]. 
Taking advantage of the pharmacological properties of ASA and ACE, 
as well as the synergism caused by CAF, the mixture of these three 
drugs is used to treat migraine, among other diseases. Migraine is an 
episodic headache disorder that produces a wide spectrum of pain 
and associated disability. Migraine attacks include both pain and 
associated symptoms (nausea, photophobia, and phonophobia) that 
have a substantial impact on daily functioning. Migraine pain is 
typically unilateral, pulsating, and often aggravated by routine 
physical activity [2]. Both environmental and genetic factors play a 
role in the development of migraine with more than two-thirds cases 
having familial history and boys are more affected than girls before 
puberty and women are more affected than men as age increases [3]. 
By the wide use of this fixed-dose combination formulation generic 
drug products with ASA, ACE, and CAF are available in the Mexican 
market. Generic drug products are off-patent formulations that 
contain the same active pharmaceutical ingredient (API) in the same 
dose as the reference drug product and they are administered by the 
same route [4]. The interchangeability of generic drugs is 
understood to mean the possibility of their mutual replacement or 
replacement of the original drug in clinical practice [5]. Drug 
products containing ACE are purchased without a prescription with 
the potential risk of poisoning due to their inappropriate 
administration. Besides, the primary degradation product of ACE is 
p-aminophenol that is reported to have teratogenic effects [6]. 
Bioequivalence studies are the best way to assure that a generic 
drug product is safe and interchangeable. Before carrying out the in 
vivo studies, dissolution studies are the basic tool to evaluate the in 
vitro release performance of drugs, especially in semi-solid or solid 
oral dosage forms. Both studies are conducted by international 
regulations based on previously published scientific information [7]. 
Literature and experimental data indicate that ASA is a highly 
soluble and highly permeable drug, leading to the assignment of this 
drug to class I of the Biopharmaceutical Classification System (BCS) 
[8]. On the other hand, by its high solubility and low permeability 
ACE is a class III drug [9]. Immediate-release solid oral dosage forms 
containing ASA or ACE, as the only API, are candidates to waiver in 
vivo studies [8, 9]. In biowaiver monographs the risk of assessing 
bioequivalence for a specific API, based on in vitro rather than in vivo 
studies, is evaluated under consideration of its biopharmaceutical 
and clinical properties [8]. 
The official in vitro dissolution test of fixed-dose combination 
formulations of ASA, ACE, and CAF is described in the USP [10]. The 
following conditions must be used: USP Apparatus 2 (paddle) at 100 
rpm and 900 ml of water as a dissolution medium (Q not less than 
75% of each drug at 60 min). Chromatographic determination is the 
recommended procedure for the quantification of all drugs. 
Several authors have summarized different analytical methods for 
the simultaneous determination of ASA, ACE, and CAF in synthetic 
mixtures or fixed-dose combination formulations [11, 12]. 
Chromatographic methods are the most accessible option but they 
require expensive equipment and generate toxic waste. 
Electrochemical methods have the advantage of presenting more 
sensibility, but electrochemical workstations as potentiostat/ 
galvanostat instruments are not widely available in pharmaceutical 
laboratories. UV spectroscopic methods are also proposed for 
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treatment of drug mixtures [13, 14]. A couple of articles describe 
double divisor-ratio spectra derivative methods for the analysis of 
the ternary mixture of ASA, ACE, and CAF. For the treatment of 
samples, one of this methods uses solutions of pH 11 [15], a medium 
that is out of physiological pH range and the other, that was 
specifically proposed for dissolution studies, has a confusing 
procedure [16]. 
In this study, a ratio-derivative spectrophotometric method with 
measurements at zero-crossing wavelengths is proposed for the 
simultaneous determination of ASA, ACE, and CAF in fixed-dose 
combination formulations. The method was developed according a 
previous UV analysis of a different ternary mixture [17] and the 
proposed UV-derivative method was applied to the treatment of 
dissolution samples. Results were compared with those obtained 
with a chromatographic method. 
The ASA, ACE, and CAF standards were purchased from Sigma-
Aldrich Co. (St. Louis MO, USA). The sodium phosphate monobasic 
and dibasic crystals, as well as methanol HPLC grade and acetic acid, 
were purchased from J. T. Baker-Mexico (Xalostoc-Mexico). The 
fixed-dose combination formulation containing ASA, ACE, and CAF 
(250 mg/250 mg/65 mg, respectively) used was Excedrin® tablets 
(GlaxoSmithKline Consumer Healthcare Mexico, S. de R. L. de C. V., 
Mexico). Mexican health authorities have established this 
commercial brand as the reference drug product to be used in 
dissolution and bioequivalence studies [18]. Content uniformity and 
assay tests were performed with the reference drug product 
according to pharmacopeial conditions [10]. 
Dissolution profiles of ASA, ACE, and CAF were obtained according 
to pharmacopeial conditions [10]. The USP Apparatus 2 (paddle) at 
100 rpm was used (Sotax AT-7 Smart, Switzerland). Tablets were 
added on 900 ml of water at 37.0±0.5 °C as dissolution medium. 
Each dissolution profile was determined with 12 replicates. After 
addition of tablets 5 ml of filtered dissolution samples were 
withdrawn at 5, 10, 15, 30, 45, and 60 min (for HPLC analysis) and 
10, 20, 30, 45, and 60 min (for UV-derivative determination). To 
compare dissolution profiles (HPLC vs. UV-derivative method) the 
model-independent parameter dissolution efficiency (DE) was 
calculated and statistically compared using a Student’s t-test [19]. 
Significant differences were found if *P<0.05. 
For chromatographic analysis, a Knauer HPLC equipment with UV 
detector and Smartline 3950 autosampler was used. A Knauer 
Eurospher II C18 column (5 µm, 150 × 4.6 mm) was used. As mobile 
phase a mixture of water: methanol: acetic acid (65:32:3 v/v/v), 
previously filtered and degased, was used (1.8 ml/min). Automatic 
samples of 30 µl were inyected into the HPLC and drugs were 
quantified at 275 nm. 
For spectrophotometric analysis, a double beam UV/Vis 
spectrophotometer (Perkin Elmer Lambda 35, Waltham MA, USA) 
with 1-cm quartz cells was used. The operating conditions for UV-
derivative analysis were first-derivative (1D) or second-derivative 
(2D) mode with scan speed of 240 nm/min, slit width 2.0 nm, and 
sampling interval 1.0 nm. 
The preparation of standard calibration curves of ASA, ACE and CAF 
were as follows: 10 mg of each drug were separately added to three 
10 ml volumetric flasks. A volumen of 5 ml of methanol was added to 
ASA and CAF flasks and a volumen of 5 ml of 0.1 M phosphate buffer 
pH 7.4 was added to ACE flask; then, all flasks were sonicated during 
10 min. After this, volumetric flasks were diluted to the mark with 
0.1 M phosphate buffer pH 7.4. From all stock solutions five 
solutions of each drug, in 0.1 M phosphate buffer pH 7.4, were 
prepared at determined interval concentrations: 5 to 25 µg/ml of 
ASA, 2.5 to 20 µg/ml of ACE, and 1 to 8 µg/ml of CAF. Then, the zero-
order spectra of all solutions, from 200 to 350 nm using 1-cm quartz 
cells, were recorded and stored. To quantify ASA and CAF, the stored 
spectra of the standard solutions of ASA and CAF were divided, 
wavelength by wavelength and by computer aid, by the stored zero-
order spectrum of a solution of 10 µg/ml of ACE. Finally, the 1D of 
the resulting ratio spectra of ASA and CAF were plotted. The zero-
crossing points to quantify ASA and CAF were identified at 244.64 
and 254.89 nm, respectively. To quantify ACE, the stored spectra of 
the standard solutions of ASA and ACE were divided by the stored 
zero-order spectrum of a solution of 4 µg/ml of CAF. Finally, the 2D 
of the resulting ratio spectra of ASA and ACE were plotted. The zero-
crossing point to quantify ACE was identified at 219.17 nm. At these 
wavelengths all analytical signals were proportional to the 
concentrations of the drugs. 
To quantify ASA, ACE, and CAF in dissolution samples, the zero-
order spectra of filtered solutions, at adequate concentrations, were 
recorded and stored. Then, the stored spectra of the samples were 
divided by the stored zero-order spectra of 10 µg/ml of ACE and 4 
µg/ml of CAF and ASA, ACE, and CAF were quantified according the 
procedures described above. 
To test linearity, three standard calibration curves of each drug were 
prepared and mean data were plotted. Data were fitted by linear 
regression analysis and the correlation coefficients and regression 
analysis of variance were calculated. Precision was demonstrated 
with the calculation of relative standard deviation (RSD): [(standard 
deviation/mean) × 100] of response factor (proporcionality of 
response vs. drug concentration). 
The accuracy and precision were tested with the preparation of 
three synthetic mixtures in 0.1 M phosphate buffer pH 7.4 from the 
stock solutions of each drug at following concentrations: 6, 18, and 
23 µg/ml of ASA; 3, 12, and 18 µg/ml of ACE; and 2.5, 5, and 7 µg/ml 
of CAF. Synthetic mixtures were analyzed with the proposed UV-
derivative method. Added vs. recovered concentrations were plotted 
and linear regression analysis was calculated. RDS at each level was 
calculated. 
The drug retention by the filter was evaluated considering response 
of ASA, ACE, and CAF before and after a solution of each drug was 
filtered. Nitrocellulose and fiberglass filters were tested. Absolute 
differences (AD): [((initial–final)/initial) × 100] were calculated with 
10 samples. The drug stability was evaluated by stored a solution of 
each drug at 4 and 25 °C during 24 and 48 h. The AD was calculated 
at each temperature and sampling time. 
The zero-order spectra of a 0.1 M phosphate buffer pH 7.4 solution 
of 15 µg/ml of ASA, 10 µg/ml of ACE, 4 µg/ml of CAF, and a synthetic 
mixture of drugs at same concentrations, are shown in fig. 1A. These 
concentrations were used as an example of the response of the 
compounds to the incidence of UV light and represent the central 
concentration of the standard calibration curves. The zero-order 
spectrum of the mixture solution demonstrated a marked 
overlapping so that the direct determination of each drug in this 
solution was not possible. The zero-crossing point of CAF was found 
at 244.64 nm. At this point, the 1D of ASA solutions were determined. 
The zero-crossing point of ASA was found at 254.89 nm. At this 
point, the 1D of CAF solutions were determined. Standard calibration 
curves of ASA and CAF, as well as the synthetic mixture, are shown 
in fig. 1B. In a 2D plot, the zero-crossing point of ASA was found at 
219.17 nm. At this point, the 2D of ACE solutions were determined. 
Standard calibration curve of ACE and the synthetic mixture are 
shown in fig. 1C. 
 
Table 1: Linearity of acetylsalicylic acid (ASA), acetaminophen (ACE), and caffeine (CAF) 
Drug Equation CI95% for intercept RSD (%) 
ASA y = 0.0105x ‒ 0.0016 ‒ 0.0053 to 0.0021 2.80 
ACE y = 0.2837x ‒ 0.0021 ‒ 0.0437 to 0.0396 2.54 
CAF y = ‒0.061x ‒ 0.0049 ‒ 0.0126 to 0.0027 3.16 
n = 3 
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Fig. 1: A) Zero-order spectra of a solution of acetylsalicylic acid (ASA), acetaminophen (ACE), caffeine (CAF), and a synthetic mixture (MIX) 
with all drugs. B) First derivative (1D) of the ratio spectra of standard curves of ASA, CAF, and MIX. C) Second derivative (2D) of the ratio 
spectra of standard curves of ASA, ACE, and MIX. Vertical lines show the zero-crossing points used to quantify each drug 
 
To test linearity, three standard calibration curves of each drug 
were prepared and mean data are shown in table 1. To test 
accuracy and precision, added vs. recovered concentrations were 
plotted and linear regressions were calculated. Results are 
shown in table 2. All linear regressions were significant 
(R2>0.999, *P<0.05). 
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Table 2: Accuracy and precision of acetylsalicylic acid (ASA), acetaminophen (ACE), and caffeine (CAF) 
Drug Equation CI95% for slope CI95% for intercept RSD (%) 
ASA y = 0.9901x ‒ 0.2745 0.74 to 1.23 ‒4.56 to 4.01 2.55 
ACE y = 1.0279x+0.0763 0.95 to 1.10 ‒0.85 to 1.04 2.11 
CAF y = 1.0629x ‒ 0.2065 0.99 to 1.13 ‒0.60 to 0.19 3.43 
n = 4 
 
The lowest values of AD to test the influence of the filter and drug 
stability are shown in table 3. The reference drug product met the 
content uniformity and assay tests described in the USP. Results are 
also shown in table 3. 
 
Table 3: AD values calculated to test influence of filter and stability with standard solutions and pharmacopeial tests to evaluate quality of 
reference drug product 
Drug Influence of filter (%)a Stability (%)b Content uniformity (min-max%)c Assay (%)d 
ASA ‒ 0.47 ‒ 16.42 94.40 to 112.65 95.73 
ACE 0.26 ‒ 16.21 92.06 to 99.94 99.81 
CAF ‒ 0.70 ‒ 50.66 96.30 to 112.62 98.88 
an = 10 with nitrocellulose filters, bn = 6 at 4 °C during 24 h, cn = 10, dn = 3 
 
Dissolution profiles of ASA, ACE, and CAF are shown in fig. 2. 
Dissolution performance of each drug, determined with the 
proposed UV-derivative method, looks like dissolution 
performance obtained with the HPLC method. As different 
sampling times were used in each experiment as well as at 5 min 
more than 80% of drug dissolved was found, no f 2  similarity 
factors were calculated. When the model-independent parameter 
DE was used to compare dissolution profiles (HPLC vs. UV-
derivative method) no significant differences were found 
(*P>0.05). Results are shown in table 4. 
 
 
Fig. 2: Dissolution profiles of acetylsalicylic acid (ASA), acetaminophen (ACE), and caffeine (CAF) using the HPLC and UV-derivative 
methods, mean value, n = 12 
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Table 4: Dissolution efficiency values calculated with dissolution data of acetylsalicylic acid (ASA), acetaminophen (ACE), and caffeine 
(CAF) 
Drug HPLC method UV-derivative method 
ASA 86.31±0.59 86.37±0.62 
ACE 90.26±0.48 89.19±0.32 
CAF 89.95±0.33 88.04±1.08 
Mean value±standard error medium. n = 12, *P>0.05 
 
The in vitro release performance of ASA, ACE, and CAF was the same 
when HPLC and UV-derivative methods were used. The proposed 
spectrophotometric method could be applied with great success for 
the simultaneous determination of these drugs in fixed-dose 
combination formulations. Several authors have suggested the use of 
DE for the comparison of dissolution profiles [19], while this model-
independent parameter is also used to establish level C in vitro/in 
vivo correlations [20]. 
The dissolution behavior of all drugs was fast (>80% dissolved at 5 
min) so this process could not be the limited-step for the absorption 
of ASA, ACE, and CAF in the body. By these results the reference drug 
product is a good parameter to compare generic formulations. There 
are some considerations for requesting a biowaiver for a fixed-dose 
combination containing a mixture of class I and III drugs. BCS-based 
biowaivers are aplicable for immediate-release fixed-dose 
combination products if they fulfill some excipients considerations e. 
g. the test product contains the same excipients as the reference 
drug product. This is due to the concern that excipients can have a 
greater impact on the absorption of low permeability drugs. The 
composition of the test product must be qualitatively the same 
(except for a different color, flavor, or preservative that could not 
affect the bioavailability) and should be quantitatively very similar 
to the reference drug product [7]. 
Several authors have pointed out that owing to the therapeutic use 
of this drug combination, it is highly needed to develop fast, simple, 
and reliable methods for simultaneous drug monitoring in 
pharmaceutical formulations [11]. Ratio-derivative spectroscopy 
was an analytical approach successfully used to simultaneously 
identify ASA, ACE, and CAF in the reference drug product. Derivative 
methods avoid the use of toxic solvents and expensive equipment 
requering specialized maintenance as a HPLC apparatus. This 
method is an easy analitical procedure by not needing any additional 
mathematical calculations or working with dissolution media out of 
the physiological pH range. The proposed spectrophotometric 
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